Drug Reposition of Non-Cancer Drugs for Cancer Treatments Through Pharmacovigilance Approach - Repurposing Drugs in Oncology Drug Reposition of Non-Cancer Drugs For Cancer Treatments Through Pharmacovigilance Approach - Repurposing Drugs in Oncology

Abstract

Objective: This study was performed to reposition the existing non-cancer drug therapy for cancer treatment, which had a well-established pharmacologic profile with better efficacy and least toxicity as an antineoplastic agent. Methods: This study for drug repositioning was performed for the drugs which are in the market since more than a decade and they are approved with their well-established efficacy and safety profile in human being. We have retrieved the source data from the United States Food and Drug Administration Adverse Event Reporting System for the past 13 years covering duration from 2004 to 2016 and analyzed the data using pharmacovigilance approach “a proposed future novel pharmaceutical tool for drug reposition” and signal management activity. Results: Signal management activity was performed for statistical analysis. It was analysed that propranolol, metformin, pioglitazone, dabigatran, and nitroglycerin which are the existing non-cancer drugs, they deserved for their direct/indirect reposition for cancer treatment and anti-neoplastic activity. Discussion: Further studies retrieving the source data from other regulatory database (e.g. Eudra Vigilance of the EMA and VigiFlow of the WHO) and post-marketing surveillance study with the same objective may adjuvant our results for the reposition of existing drugs by pharmacovigilance approach.